Anticancer activities of histone deacetylase inhibitors

Nature Reviews Drug Discovery

Volumn 5, Issue 9, 2006, Pages 769-784

  Bolden, Jessica E ^a,b   Peart, Melissa J ^c   Johnstone, Ricky W ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 4 N ACETYLDINALINE; 6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; AMIDOHYDROLASE INHIBITOR; APICIDIN; BUTYRIC ACID; CG 1521; DEPSIPEPTIDE; DEPUDECIN; EPOTHILONE B; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; LBH 589; MGCD 0103; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; NONHISTONE PROTEIN; OXAMFLATIN; PIVALOYLOXYMETHYL BUTYRATE; PYROXAMIDE; SK 7041; SK 7068; TACEDINALINE; TRAPOXIN A; TRICHOSTATIN A; TRIFLUOROMETHYLKETONE; TUBACIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; CELL CYCLE ARREST; CHROMATIN ASSEMBLY AND DISASSEMBLY; CLINICAL TRIAL; DRUG POTENCY; DRUG POTENTIATION; DRUG SYNTHESIS; DRUG TARGETING; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; HUMAN; IMMUNOMODULATION; MOLECULAR BIOLOGY; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REVIEW; T CELL LYMPHOMA; TUMOR IMMUNITY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; NEOPLASMS;

EID: 33748451151     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2133     Document Type: Review

References (205)

1. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70. (2000).
2. Kinzler, K. W. & Vogelstein, B. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 386, 761-763 (1997).
3. Lund, A. H. & van Lohuizen, M. Epigenetics and cancer. Genes Dev. 18, 2315-2335 (2004).
4. Baylin, S. B. & Ohm, J. E. Epigenetic gene silencing in cancer- a mechanism for early oncogenic pathway addiction? Nature Rev. Cancer 6, 107-116 (2006).
5. Nightingale, K. P., O'Neill, L. P. & Turner, B. M. Histone modifications: Signalling receptors and potential elements of a heritable epigenetic code. Curr. Opin. Genet. Dev. 16, 125-136 (2006).
6. Roth, S. Y., Denu, J. M. & Allis, C. D. Histone acetyltransferases. Annu. Rev. Biochem. 70, 81-120 (2001).
7. Thiagalingam, S. et al. Histone deacetylases: Unique players in shaping the epigenetic histone code. Ann. NY Acad. Sci. 983, 84-100 (2003).
8. Pandolfi, P. P. Histone deacetylases and transcriptional therapy with their inhibitors. Cancer Chemother. Pharmacol. 48 (Suppl. 1), S17-S19 (2001).
9. Marks, P. A. & Jiang, X. Histone deacetylase inhibitors in programmed cell death and cancer therapy. Cell Cycle 4, 549-551 (2005).
10. Lindemann, R. K., Gabrielli, B. & Johnstone, R. W. Histone-deacetylase inhibitors for the treatment of cancer. Cell Cycle 3, 779-788 (2004).
11. Jabbour, E. J. & Giles, F. J. New agents in myelodysplastic syndromes. Curr. Hematol. Rep. 4, 191-199 (2005).
12. Lin, R. J., Sternsdorf, T., Tini, M. & Evans, R. M. Transcriptional regulation in acute promyelocytic leukemia. Oncogene 20, 7204-7215 (2001).
13. Cote, S. et al. Response to histone deacetylase inhibition of novel PML/ RARα mutants detected in retinoic acid-resistant APL cells. Blood 100, 2586-2596 (2002).
14. He, L. Z. et al. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J. Clin. Invest. 108, 1321-1330 (2001).
15. Warrell, R. P., Jr., He, L. Z., Richon, V., Calleja, E. & Pandolfi, P. P. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl Cancer Inst. 90 1621-1625 (1998).
16. Ferrara, F. F. et al. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res. 61, 2-7 (2001).
17. Pasqualucci, L. et al. Molecular pathogenesis of non-Hodgkin's lymphoma: the role of Bcl-6. Leuk. Lymphoma 44 (Suppl. 3), S5-S12 (2003).
18. Halkidou, K. et al. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 59, 177-189 (2004).
19. Choi, J. H. et al. Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J. Cancer Res. 92, 1300-1304 (2001).
20. Wilson, A. J. et al. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J. Biol. Chem. 281, 13548-13558 (2006).
21. Zhang, Z. et al. Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast. Breast Cancer Res. Treat 94, 11-16 (2005).
22. Zhu, P. et al. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 5, 455-463 (2004).
23. Huang, B. H. et al. Inhibition of histone deacetylase 2 increases apoptosis and p21 Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ. 12, 395-404 (2005).
24. Song, J. et al. Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS 113, 264-268 (2005).
25. Zhang, Z. et al. HDAC6 expression is correlated with better survival in breast cancer. Clin. Cancer Res. 10, 6962-6968 (2004).
26. Glaser, K. B. et al. Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem. Biophys. Res. Commun. 310, 529-536 (2003).
27. Insinga, A. et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nature Med. 11, 71-76 (2005).
28. Fraga, M. F. et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nature Genet. 37, 391-400 (2005).
29. Leder, A., Orkin, S. & Leder, P. Differentiation of erythroleukemic cells in the presence of inhibitors of DNA synthesis. Science 190, 893-894 (1975).
30. Riggs, M. G., Whittaker, R. G., Neumann, J. R. & Ingram, V. M. n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells. Nature 268, 462-464 (1977).
31. Yoshida, M., Kijima, M., Akita, M. & Beppu, T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 265, 17174-17179 (1990).
32. Richon, V. M. et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl Acad. Sci. USA 95, 3003-3007 (1998).
33. Fischle, W. et al. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol. Cell 9, 45-57 (2002).
34. Hu, E. et al. Identification of novel isoform-selective inhibitors within class I histone deacetylases. J. Pharmacol. Exp. Ther. 307, 720-728 (2003).
35. Li, J. et al. Expression and functional characterization of recombinant human HDAC1 and HDAC3. Life Sci. 74, 2693-2705 (2004).
36. Furumai, R. et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 62, 4916-4921 (2002).
37. Qian, D. Z. et al. Targeting tumor angiogenesis with histone deacetylase inhibitors: The hydroxamic acid derivative LBH589. Clin. Cancer Res. 12, 634-642 (2006).
38. Warrener, R. et al. Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints. FASEB J. 17, 1550-1552 (2003).
39. Haggarty, S. J., Koeller, K. M., Wong, J. C., Grozinger, C. M. & Schreiber, S. L. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc. Natl Acad. Sci. USA 100, 4389-4394 (2003).
40. Blagosklonny, M. V. et al. Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol. Cancer Ther. 1, 937-941 (2002).
41. Drummond, D. C. et al. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu. Rev. Pharmacol. Toxicol. 45, 495-528 (2005).
42. Dokmanovic, M. & Marks, P. A. Prospects: Histone deacetylase inhibitors. J. Cell. Biochem. 96, 293-304 (2005).
43. Kelly, W. K. & Marks, P. A. Drug insight: Histone deacetylase inhibitors - development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nature Clin. Pract. Oncol. 2, 150-157 (2005).
44. Kelly, W. K., O'Connor, O. A. & Marks, P. A. Histone deacetylase inhibitors: From target to clinical trials. Expert Opin. Investig. Drugs 11, 1695-1713 (2002).
45. Johnstone, R. W. Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer. Nature Rev. Drug Discov. 1, 287-299 (2002).
46. Minucci, S. & Pelicci, P. G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nature Rev. Cancer 6, 38-51 (2006).
47. Willis, S. N. & Adams, J. M. Life in the balance: How BH3-only proteins induce apoptosis. Curr. Opin. Cell Biol. 17, 617-625 (2005).
48. Ruefli, A. A. et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc. Natl Acad. Sci. USA 98, 10833-10838 (2001).
49. Peart, M. J. et al. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res. 63, 4460-4471 (2003).
50. Mitsiades, N. et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 101, 4055-4062 (2003).
51. Zhang, Y., Adachi, M., Kawamura, R. & Imai, K. Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis. Cell Death Differ. 13, 129-140 (2006).
52. Zhao, Y. et al. Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc. Natl Acad. Sci. USA 102, 16090-16095 (2005).
53. Rosato, R. R., Almenara, J. A. & Grant, S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21 CIP1/WAF1 1. Cancer Res. 63, 3637-3645 (2003).
54. Sade, H. & Sarin, A. Reactive oxygen species regulate quiescent T-cell apoptosis via the BH3-only proapoptotic protein BIM. Cell Death Differ. 11, 416-423 (2004).
55. Marks, P. A., Miller, T. & Richon, V. M. Histone deacetylases. Curr. Opin. Pharmacol. 3, 344-351 (2003).
56. Marks, P. et al. Histone deacetylases and cancer: Causes and therapies. Nature Rev. Cancer 1, 194-202 (2001).
57. Marks, P. A., Richon, V. M. & Rifkind, R. A. Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells. J. Natl Cancer Inst. 92, 1210-1216 (2000).
58. Gabrielli, B. G., Johnstone, R. W. & Saunders, N. A. Identifying molecular targets mediating the anticancer activity of histone deacetylase inhibitors: A work in progress. Curr Cancer Drug Targets 2, 337-353 (2002).
59. Vrana, J. A. et al. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21 CIP1, but independent of p53. Oncogene 18, 7016-7025 (1999).
60. Richon, V. M., Sandhoff, T. W., Rifkind, R. A. & Marks, P. A. Histone deacetylase inhibitor selectively induces p21 WAF1 expression and gene-associated histone acetylation. Proc. Natl Acad. Sci. USA 97, 10014-10019 (2000).
61. Kim, Y. B., Lee, K. H., Sugita, K., Yoshida, M. & Horinouchi, S. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene 18, 2461-2470 (1999).
62. Qiu, L. et al. Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol. Biol. Cell. 11, 2069-2083 (2000).
63. Sandor, V. et al. P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br. J. Cancer 83, 817-825 (2000).
64. Glaser, K. B. et al. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: Defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol. Cancer Ther. 2, 151-163 (2003).
65. Chen, Z. et al. Induction and superinduction of growth arrest and DNA damage gene 45 (GADD45) α and β messenger RNAs by histone deacetylase inhibitors trichostatin A (TSA) and butyrate in SW620 human colon carcinoma cells. Cancer Lett. 188, 127-140 (2002).
66. Jaboin, J. et al. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res. 62, 6108-6115 (2002).
67. Burgess, A. J. et al. Up-regulation of p21 (WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity. Mol. Pharmacol. 60, 828-837 (2001).
68. Taddei, A., Roche, D., Bickmore, W. A. & Almouzni, G. The effects of histone deacetylase inhibitors on heterochromatin: Implications for anticancer therapy? EMBO Rep. 6, 520-524 (2005).
69. Pili, R., Kruszewski, M. P., Hager, B. W., Lantz, J. & Carducci, M. A. Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res. 61, 1477-1485 (2001).
70. Sasakawa, Y. et al. Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors. Biochem. Pharmacol. 66, 897-906 (2003).
71. Michaelis, M. et al. Valproic acid inhibits angiogenesis in vitro and in vivo. Mol. Pharmacol. 65, 520-527 (2004).
72. Rossig, L. et al. Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis. Circ. Res. 91, 837-844 (2002).
73. Deroanne, C. F. et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21, 427-436 (2002).
74. Crazzolara, R. et al. Histone deacetylase inhibitors potently repress CXCR4 chemokine receptor expression and function in acute lymphoblastic leukaemia. Br. J. Haematol. 119, 965-969 (2002).
75. Kim, S. H. et al. Apicidin is a histone deacetylase inhibitor with anti-invasive and anti-angiogenic potentials. Biochem. Biophys. Res. Commun. 315, 964-970 (2004).
76. Liu, L. T., Chang, H. C., Chiang, L. C. & Hung, W. C. Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Res. 63, 3069-3072 (2003).
77. Klisovic, D. D. et al. Depsipeptide inhibits migration of primary and metastatic uveal melanoma cell lines in vitro: A potential strategy for uveal melanoma. Melanoma Res. 15, 147-153 (2005).
78. Coradini, D. et al. Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But. Clin. Cancer Res. 10, 4822-4830 (2004).
79. Maeda, T., Towatari, M., Kosugi, H. & Saito, H. Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. Blood 96, 3847-3856 (2000).
80. Magner, W. J. et al. Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J. Immunol. 165, 7017-7024 (2000).
81. Armeanu, S. et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res. 65, 6321-6329 (2005).
82. Skov, S. et al. Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res. 65, 11136-11145 (2005).
83. Reddy, P. et al. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc. Natl Acad. Sci. USA 101, 3921-3926 (2004).
84. Nusinzon, I. & Horvath, C. M. Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1. Proc. Natl Acad. Sci. USA 100, 14742-14747 (2003).
85. Yuan, Z. L., Guan, Y. J., Chatterjee, D. & Chin, Y. E. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 307, 269-273 (2005).
86. Chen, L., Fischle, W., Verdin, E. & Greene, W. C. Duration of nuclear NF-κB action regulated by reversible acetylation. Science 293, 1653-1657 (2001).
87. Johnstone, R. W. & Licht, J. D. Histone deacetylase inhibitors in cancer therapy: Is transcription the primary target? Cancer Cell 4, 13-18 (2003).
88. Gu, W. & Roeder, R. G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90, 595-606 (1997).
89. Martinez-Balbas, M. A., Bauer, U. M., Nielsen, S. J., Brehm, A. & Kouzarides, T. Regulation of E2F1 activity by acetylation. EMBO J. 19, 662-671 (2000).
90. Luo, J., Su, F., Chen, D., Shiloh, A. & Gu, W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 408, 377-381 (2000).
91. Pediconi, N. et al. Differential regulation of E2F1 apoptotic target genes in response to DNA damage. Nature Cell Biol. 5, 552-558 (2003).
92. Costanzo, A. et al. DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol. Cell 9, 175-186 (2002).
93. Finzer, P. et al. HDAC inhibitors trigger apoptosis in HPV-positive cells by inducing the E2F-p73 pathway. Oncogene 23, 4807-4817 (2004).
94. Hershko, T. & Ginsberg, D. Up-regulation of Bcl-2 homology 3 (BH3 -only proteins by E2F1 mediates apoptosis. J. Biol. Chem. 279, 8627-8634 (2004).
95. Chipuk, J. E. & Green, D. R. Dissecting p53-dependent apoptosis. Cell Death Differ. 13, 994-1002 (2006).
96. Tomita, Y. et al. WTp53 but not tumor-derived mutants bind to BCL2 via the DNA binding domain and induce mitochondrial permeabilization. J. Biol. Chem. 281, 8600-8606 (2006).
97. Xu, Y. Regulation of p53 responses by posttranslational modifications. Cell Death Differ. 10, 400-403 (2003).
98. Terui, T. et al. Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic cell death by histone deacetylase inhibitors. Cancer Res. 63, 8948-8954 (2003).
99. Blagosklonny, M. V. et al. Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors. Cancer Res. 65, 7386-7392 (2005).
100. Chen, C., Edelstein, L. C. & Gelinas, C. The Rel/NF-κB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol. Cell Biol. 20, 2687-2695 (2000).
101. Stehlik, C. et al. Nuclear factor (NF)-κB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor α-induced apoptosis. J. Exp. Med. 188, 211-26 (1998).
102. Kramer, O. H. et al. Acetylation of Stat1 modulates NF-κB activity. Genes Dev. 20, 473-485 (2006).
103. Medina, V. et al. Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/ cytochrome c-dependent pathway. Cancer Res. 57, 3697-3707 (1997).
104. Glick, R. D. et al. Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. Cancer Res. 59, 4392-4399 (1999).
105. Kwon, S. H. et al. Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells. J. Biol. Chem. 277, 2073-2080 (2002).
106. Glozak, M. A., Sengupta, N., Zhang, X. & Seto, E. Acetylation and deacetylation of non-histone proteins. Gene 363, 15-23 (2005).
107. Cohen, H. Y. et al. Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol. Cell 13, 627-638 (2004).
108. Subramanian, C., Opipari, A. W., Jr., Bian, X., Castle, V. P. & Kwok, R. P. Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors. Proc. Natl Acad. Sci. USA 102, 4842-4847 (2005).
109. Canettieri, G. et al. Attenuation of a phosphorylation-dependent activator by an HDAC-PP1 complex. Nature Struct. Biol. 10, 175-181 (2003).
110. Brush, M. H., Guardiola, A., Connor, J. H., Yao, T. P. & Shenolikar, S. Deactylase inhibitors disrupt cellular complexes containing protein phosphatases and deacetylases. J. Biol. Chem. 279, 7685-7691 (2004).
111. Chen, C. S., Weng, S. C., Tseng, P. H. & Lin, H. P. Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J. Biol. Chem. 280, 38879-38887 (2005).
112. Whitesell, L. & Lindquist, S. L. HSP90 and the chaperoning of cancer. Nature Rev. Cancer 5, 761-772 (2005).
113. Budillon, A., Bruzzese, F., Di Gennaro, E. & Caraglia, M. Multiple-target drugs: Inhibitors of heat shock protein 90 and of histone deacetylase. Curr. Drug Targets 6, 337-351 (2005).
114. Kovacs, J. J. et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol. Cell 18, 601-67 (2005).
115. Fuino, L. et al. Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol. Cancer Ther. 2, 971-984 (2003).
116. Nimmanapalli, R. et al. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or-refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res. 63, 5126-5135 (2003).
117. Bali, P. et al. Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3. Clin. Cancer Res. 10, 4991-4997 (2004).
118. Yu, X. et al. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J. Natl Cancer Inst. 94, 504-513 (2002).
119. Hideshima, T. et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc. Natl Acad. Sci. USA 102, 8567-8572 (2005).
120. Bali, P. et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: A novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem. 280, 26729-26734 (2005).
121. Bhalla, K. N. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J. Clin. Oncol. 23, 3971-3993 (2005).
122. Reynolds, C. P. & Lemons, R. S. Retinoid therapy of childhood cancer. Hematol. Oncol. Clin. North Am. 15, 867-910 (2001).
123. Coffey, D. C. et al. The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. Cancer Res. 61, 3591-3594 (2001).
124. Cameron, E. E., Bachman, K. E., Myohanen, S., Herman, J. G. & Baylin, S. B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nature Genet. 21, 103-107 (1999).
125. Gore, S. D. et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 66, 6361-6369 (2006).
126. Kim, M. S. et al. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res. 63, 7291-7300 (2003).
127. Catley, L. et al. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood 102, 2615-2622 (2003).
128. Chauhan, D. et al. Apaf-1/cytochrome c-independent and Smac-dependent induction of apoptosis in multiple myeloma (MM) cells. J. Biol. Chem. 276, 24453-24456 (2001).
129. Loprevite, M. et al. In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines. Oncol. Res. 15, 39-48 (2005).
130. Pauer, L. R. et al. Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors. Cancer Invest. 22, 886-896 (2004).
131. Zhang, X. D., Gillespie, S. K., Borrow, J. M. & Hersey, P. The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. Mol. Cancer Ther. 3, 425-435 (2004).
132. Nakata, S. et al. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 23, 6261-6271 (2004).
133. Inoue, S. et al. Histone of deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ. 11 (Suppl. 2), S193-S206 (2004).
134. Rosato, R. R., Almenara, J. A., Dai, Y. & Grant, S. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol. Cancer Ther. 2, 1273-1284 (2003).
135. Guo, F. et al. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res. 64, 2580-2589 (2004).
136. Singh, T. R., Shankar, S. & Srivastava, R. K. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene 24, 4609-4623 (2005).
137. Watanabe, K., Okamoto, K. & Yonehara, S. Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP. Cell Death Differ. 12, 10-18 (2005).
138. Kim, E. H. et al. Sodium butyrate sensitizes human glioma cells to TRAIL-mediated apoptosis through inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP. Oncogene 24, 6877-6889 (2005).
139. Earel, J. K., Jr., VanOosten, R. L. & Griffith, T. S. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells. Cancer Res. 66, 499-507 (2006).
140. Rosato, R. R., Almenara, J. A., Yu, C. & Grant, S. Evidence of a functional role for p21 WAF1/CIP1 down-regulation in synergistic antileukemic interactions between the histone deacetylase inhibitor sodium butyrate and flavopiridol. Mol. Pharmacol. 65, 571-581 (2004).
141. Rahmani, M. et al. Inhibition of PI-3 kinase sensitizes human leukemic cells to histone deacetylase inhibitor-mediated apoptosis through p44/42 MAP kinase inactivation and abrogation of p21 (CIP1/WAF1) induction rather than AKT inhibition. Oncogene 22, 6231-6242 (2003).
142. Yu, C., Dasmahapatra, G., Dent, P. & Grant, S. Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells. Leukemia 19, 1579-1589 (2005).
143. Deininger, M., Buchdunger, E. & Druker, B. J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105, 2640-2653 (2005).
144. Yu, C. et al. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and-resistant Bcr/Abl+ human myeloid leukemia cells. Cancer Res. 63, 2118-2126 (2003).
145. Nimmanapalli, R., Fuino, L., Stobaugh, C., Richon, V. & Bhalla, K. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood 101, 3236-3239 (2003).
146. Kim, J. S. et al. Apicidin potentiates the imatinib-induced apoptosis of Bcr-Abl-positive human leukaemia cells by enhancing the activation of mitochondria-dependent caspase cascades. Br. J. Haematol. 124, 166-178 (2004).
147. George, P. et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 105, 1768-1776 (2005).
148. Kawano, T. et al. Depsipeptide enhances imatinib mesylate-induced apoptosis of Bcr-Abl-positive cells and ectopic expression of cyclin D1, c-Myc or active MEK abrogates this effect. Anticancer Res. 24, 2705-2712 (2004).
149. Rahmani, M. et al. Coadministration of the heat shock protein 90 antagonist 17-allylamino-17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. Cancer Res. 63, 8420-8427 (2003).
150. Rahmani, M. et al. Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change. Mol. Pharmacol. 67, 1166-1176 (2005).
151. Yu, C. et al. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood 102, 3765-3774 (2003).
152. Pei, X. Y., Dai, Y. & Grant, S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin. Cancer Res. 10, 3839-3852 (2004).
153. Adachi, M. et al. Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells. Clin. Cancer Res. 10, 3853-3862 (2004).
154. Nawrocki, S. T. et al. Aggresome disruption: A novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res. 66, 3773-3781 (2006).
155. Wang, X. et al. 17-allylamino-17-demethoxygeldanamycin synergistically potentiates tumor necrosis factor-induced lung cancer cell death by blocking the nuclear factor-κB pathway. Cancer Res. 66, 1089-1095 (2006).
156. Kawaguchi, Y. et al. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115, 727-738 (2003).
157. Kopito, R. R. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol. 10, 524-530 (2000).
158. Zhang, Y., Jung, M. & Dritschilo, A. Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors. Radiat. Res. 161, 667-674 (2004).
159. Kim, J. H., Shin, J. H. & Kim, I. H. Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor. Int. J. Radiat. Oncol. Biol. Phys. 59, 1174-1180 (2004).
160. Camphausen, K., Scott, T., Sproull, M. & Tofilon, P. J. Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation. Clin. Cancer Res. 10, 6066-6071 (2004).
161. Camphausen, K. et al. Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int. J. Cancer 114, 380-36 (2005).
162. Nome, R. V. et al. Cell cycle checkpoint signaling involved in histone deacetylase inhibition and radiation-induced cell death. Mol. Cancer Ther. 4, 1231-1238 (2005).
163. Karagiannis, T. C., Kn, H. & El-Osta, A. The Histone Deacetylase Inhibitor, Trichostatin A, Enhances Radiation Sensitivity and Accumulation of γH2A. X. Cancer Biol. Ther. 4, 787-793 (2005).
164. Shiloh, Y. ATM and related protein kinases: Safeguarding genome integrity. Nature Rev. Cancer 3, 155-168 (2003).
165. Bakkenist, C. J. & Kastan, M. B. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421, 499-506 (2003).
166. Kim, G. D. et al. Sensing of ionizing radiation-induced DNA damage by ATM through interaction with histone deacetylase. J. Biol. Chem. 274, 31127-31130 (1999).
167. Munshi, A. et al. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin. Cancer Res. 11, 4912-4922 (2005).
168. Yaneva, M., Li, H., Marple, T. & Hasty, P. Non-homologous end joining, but not homologous recombination, enables survival for cells exposed to a histone deacetylase inhibitor. Nucleic Acids Res. 33, 5320-5330 (2005).
169. Chung, Y. L., Wang, A. J. & Yao, L. F. Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: Implications for increasing therapeutic gain in cancer radiotherapy. Mol. Cancer Ther. 3, 317-325 (2004).
170. Vannini, A. et al. Crystal structure of a eukaryotic zinc-dependent histone deacetylase human HDAC8 complexed with a hydroxamic acid inhibitor. Proc. Natl Acad. Sci. USA 101, 15064-15069 (2004).
171. Hubbert, C. et al. HDAC6 is a microtubule-associated deacetylase. Nature 417, 455-458 (2002).
172. Gao, L., Cueto, M. A., Asselbergs, F. & Atadja, P. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J. Biol. Chem. 277, 25748-25755 (2002).
173. Johnstone, R. W., Ruefli, A. A. & Lowe, S. W. Apoptosis: A link between cancer genetics and chemotherapy. Cell 108, 153-164 (2002).
174. Cory, S. & Adams, J. M. The Bcl2 family: Regulators of the cellular life-or-death switch. Nature Rev. Cancer 2, 647-656 (2002).
175. Cory, S., Huang, D. C. & Adams, J. M. The Bcl-2 family: Roles in cell survival and oncogenesis. Oncogene 22, 8590-8607 (2003).
176. Butler, L. M. et al. Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin. Cancer Res. 7, 962-970 (2001).
177. Park, J. H. et al. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation. Clin. Cancer Res. 10, 5271-5281 (2004).
178. Furumai, R. et al. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc. Natl Acad. Sci. USA 98, 87-92 (2001).
179. Kwon, H. J., Owa, T., Hassig, C. A., Shimada, J. & Schreiber, S. L. Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase. Proc. Natl Acad. Sci. USA 95, 3356-3361 (1998).
180. Imai, T. et al. FR901228 induces tumor regression associated with induction of Fas ligand and activation of Fas signaling in human osteosarcoma cells. Oncogene 22, 9231-9242 (2003).
181. Nebbioso, A. et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nature Med. 11, 77-84 (2005).
182. Sutheesophon, K. et al. Involvement of the tumor necrosis factor (TNF)/ TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228). J. Cell Physiol. 203, 387-397 (2005).
183. Bernhard, D. et al. Apoptosis induced by the histone deacetylase inhibitor sodium butyrate in human leukemic lymphoblasts. FASEB J. 13, 1991-2001 (1999).
184. Rosato, R. R. et al. The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide. Mol. Pharmacol. 69, 216-225 (2006).
185. Mitsiades, C. S. et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications. Proc. Natl Acad. Sci. USA 101, 540-545 (2004).
186. Peart, M. J. et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc. Natl. Acad. Sci. USA 102, 3697-3702 (2005).
187. Moore, P. S. et al. Gene expression profiling after treatment with the histone deacetylase inhibitor trichostatin A reveals altered expression of both pro- and anti-apoptotic genes in pancreatic adenocarcinoma cells. Biochim. Biophys. Acta 1693, 167-176 (2004).
188. Duan, H., Heckman, C. A. & Boxer, L. M. Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol. Cell Biol. 25, 1608-1619 (2005).
189. Tan, J. et al. Apoptosis signal-regulating kinase 1 is a direct target of E2F1 and contributes to histone deacetylase inhibitor- induced apoptosis through positive feedback regulation of E2F1 apoptotic activity. J. Biol. Chem. 281, 10508-10515 (2006).
190. Rahmani, M. et al. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Res. 65, 2422-2432 (2005).
191. Ungerstedt, J. S. et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc. Natl Acad. Sci. USA 102, 673-678 (2005).
192. Butler, L. M. et al. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc. Natl Acad. Sci. USA 99, 11700-11705 (2002).
193. Zhu, W. G. & Otterson, G. A. The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr. Med. Chem. Anti-Canc Agents 3, 187-199 (2003).
194. Keen, J. C. et al. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor α (ER) in ER negative human breast cancer cells in combination with 5-aza 2′-deoxycytidine. Breast Cancer Res. Treat 81, 177-186 (2003).
195. Shaker, S., Bernstein, M., Momparler, L. F. & Momparler, R. L. Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2′-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells. Leuk. Res. 27, 437-444 (2003).
196. Klisovic, M. I. et al. Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells. Leukemia 17, 350-358 (2003).
197. Boivin, A. J., Momparler, L. F., Hurtubise, A. & Momparler, R. L. Antineoplastic action of 5-aza-2′-deoxycytidine and phenylbutyrate on human lung carcinoma cells. Anticancer Drugs 13, 869-874 (2002).
198. Minucci, S. et al. A histone deacetylase inhibitor potentiates retinoid receptor action in embryonal carcinoma cells. Proc. Natl Acad. Sci. USA 94, 11295-11300 (1997).
199. Kitazono, M., Bates, S., Fok, P., Fojo, T. & Blagosklonny, M. V. The histone deacetylase inhibitor FR901228 (desipeptide) restores expression and function of pseudo-null p53. Cancer Biol. Ther. 1, 665-668 (2002).
200. Zhang, X. D., Gillespie, S. K., Borrow, J. M. & Hersey, P. The histone deacetylase inhibitor suberic bishydroxamate: A potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis. Biochem. Pharmacol. 66, 1537-1545 (2003).
201. Nguyen, D. M. et al. Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells. Clin. Cancer Res. 10, 1813-1825 (2004).
202. Rosato, R. R., Wang, Z., Gopalkrishnan, R. V., Fisher, P. B. & Grant, S. Evidence of a functional role for the cyclin-dependent kinase-inhibitor p21 WAF1/CIP1/MDA6 in promoting differentiation and preventing mitochondrial dysfunction and apoptosis induced by sodium butyrate in human myelomonocytic leukemia cells (U937). Int. J. Oncol. 19, 181-191 (2001).
203. Almenara, J., Rosato, R. & Grant, S. Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Leukemia 16, 1331-1343 (2002).
204. Dai, Y., Rahmani, M., Dent, P. & Grant, S. Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-κB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation. Mol. Cell Biol. 25, 5429-5444 (2005).
205. Garcia-Manero, G. et al. A Phase I study of the histone deacetylase inhibitor MGCD0103 (MG-0103) given as a three-times weekly oral dose in patients with leukemia or myelodysplastic syndromes (MDS). Blood 106 A4639 (2005).